anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:To obtain the titled bath agent exhibiting natural and excellent skin- sterilizing effect, having high stability and storable for a long period at normal temperature, by extracting a whole citrus fruit with SAKE (Japanese rice wine) and using at least one kind of the extract as a component. CONSTITUTION:The objective bath agent contains the extracted liquid produced by extracting whole fruits of navel orange, Citrus iyo, Citrus hassaku and kumquats with SAKE. A bath agent having improved fragrance, body-warming activity and medicinal effect can be produced by carrying out the extraction in the presence of a whole lemon fruit and wormwood and aloe each divided into two. It is essential to use a young bud of wormwood in the above procedure. Examples of concrete symptoms to which the agent is applicable are heat rashes, chappy skin, ringworm, bruise, shoulder discomfort, shoulder strain, neuralgia, eczema, frostbite, cold constitution, athlete&#39;s foot, lumbago, rheumatism, etc. EFFECT:The extracted liquid is transparent and free from undesirable components and the necessary antibacterial components are exclusively and surely extracted because the citrus fruit is used in its entirety.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a functional composition for oral administration, effective for the restoration of abraded cartilage, the lessening of pain and the reduction of stress caused by arthralgia to assure a comfortable life with quiet and deep sleep, giving comprehensive satisfaction and common sensation, having quick action and takable as a food.  &lt;P&gt;SOLUTION: The functional composition for oral administration contains 0.01-100 pts. wt. of taurine and/or 0.01-100 pts. wt. of γ-aminobutyric acid per 100 pts. wt. of glucosamine or its edible salt. More preferably, the functional composition further contains 0.5-1,500 pts. wt. of at least one kind of component selected from mucopolysaccharide, mucopolysaccharide complex and mucopolysaccharide protein complex and 0.5-500 pts. wt. of a salicin-containing vegetable extract.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI
NEW MATERIAL:The isoflavan derivative of formula (R1 is methyl; R2 is methyl or H). USE:Useful as a muscle relaxant. It has microcirculation improving action and exhibits hypotensive action against essential hypertension, coronary vasodilating action, cerebral circulation improving action, action to ameliorate peripheral blood flow disorder (Raynaud&#39;s disease, Buerger disease etc.), etc. PREPARATION:KANZO (Glycyrrhiza glauba) is immersed in an organic solvent, the extract is treated by liquid chromatography an the compound of formula is separated from the eluate. The organic solvent is methanol, ethanol, acetone, etc., or their mixture. KANZO is a leguminous plant and its root and stolon have been long used as herb drugs.
The present invention discloses a kind of Gynura procumbens (Lour.) Merr tea alleviated smoking and cause cough, it is prepared from the following raw materials in parts by weight：75~80 parts of Gynura procumbens (Lour.) Merr cured leaf, 8~10 parts of honeysuckle, 5~8 parts of Siraitia grosvenorii, 5~10 parts of campanulaceae, 1~3 part of radix glycyrrhizae；And the preparation method that above-mentioned alleviation smoking causes the Gynura procumbens (Lour.) Merr tea of cough is disclosed, it is that cured leaf first is made in Gynura procumbens (Lour.) Merr fresh leaf, then the composite extract of remaining each raw material is uniformly sprayed on Gynura procumbens (Lour.) Merr cured leaf, is finally packed.Gynura procumbens (Lour.) Merr tea prepared by the present invention is suitable for lung&#39;s malaise symptoms such as cough, expectoration, chest asthma, repeated infection caused by lung&#39;s malaise symptoms such as cough caused by smoking reason and bronchitis and bronchiectasis, the harm to smoking population lung is reduced, improves people&#39;s life life quality.
2,4&#39;-Dimethyl-3-piperidino propiophenone (tolperisone) and their pharmaceutical acceptable salts production involves converting 4-methylpropiophenone with piperidinhydrochloride and 1,2-dioxolane in presence of one or multiple acids as catalyst in a solvent. The tolperisone raw product is filtered in the form of pharmaceutical compatible hydrochlorides, hydrates, and addition salts after cooling the reaction mixture. A part is reduced to 2-methyl-1-(4-methylphenyl) propenone (4-MMPPO) by recrystallization of the tolperisone raw product in presence of a counter solvent and absorbent. Independent claims are included for: (1) a method for producing a pharmaceutical formulation, which involves blending tolperisone as active substance under water-free conditions in one or multiple solvents with a water-free additive in the form of a pharmaceutical compatible acid, preferably citric acid; (2) a controlled release (CR) formulation, which comprises a core component and a retard coating; and (3) a transdermal therapeutic system, which comprises a reservoir layer containing tolperisone as active substance in pure form. ACTIVITY : Neuroprotective; Nootropic. MECHANISM OF ACTION : None given.
9-Thia-, 9-oxothia- and 9-dioxothia-11,12-secoprostaglandins of the formula II &lt; IMAGE &gt; are prepared, wherein A, R&lt;4&gt;, R&lt;9&gt; and R&lt;10&gt; are defined in Claim 1 and m is 0, 1 or 2. If n = 0, these compounds are obtained by reacting, in optional sequence, di-tert.-butyl malonate with two different appropriate halogeno-esters in order to introduce the two side chains. The reaction product obtained is a disubstituted malonic ester. By heating this ester in the presence of a strong acid, the corresponding substituted decarboxylated malonic acid derivative is obtained. This derivative is then reacted with bromine in the presence of mercury(II) oxide, whereby the carboxyl group is replaced by bromine. The resulting substituted bromo-ester is then reacted with the alkali metal salt of a mercaptan of the formula R&lt;9&gt;SH, and finally the ester group is hydrolysed. To prepare 9-oxothia- and 9-dioxothia-11,12-secoprostaglandins, the 9-thia-11,12-secoprostaglandins are oxidised. The compounds exhibit a prostaglandin-like activity and may be used for the treatment of skin diseases.
A novel product for headache relief and use of the product to treat headaches is disclosed herein. The product may be applied topically, and may be used for acute treatment of headaches to provide a safe, effective, and natural alternative to traditional therapies used to treat acute headache syndromes. The product comprises one or more herbal therapeutic agents. In some embodiments, the one or more herbal therapeutic agents may be combined with allopathic or other traditional headache therapies. In preferred embodiments, the product is applied to select myofascial trigger points. (MTPs) on the temporal, frontal, mastoid, and cervical regions. The product may be available over-the-counter or otherwise may be available without a physician&#39;s prescription.
MEDICAL SCHEME MEMBER : Prior Med e Card - When Member attends Health Service Provider including Doctor, use special Short Code Number designated to send in Mobile Message of the Practice Number, Via Prior&#39;s Systems &amp; utilizing Cellular Gateway, or WASP etc transfer message to Scheme Administration system, using Members Cell Number - to identify Unique Membership &amp; other significant information, including Premium payments, outstanding Benefits etc - Do auto Validation of Member &amp; other required criteria - and send Validation Message back to Health Service Provider - Cell Phone. All Automatic - all in virtual real time. NON MEDICAL SCHEME MEMBER Prior Med e Health - Mobile Health Voucher where Person acquires a Voucher via various methods, cash from outlet, via Employer, on Credit /Debit Card etc. All purchases directed to Prior Systems - who then issue Virtual Health Voucher Code Number to the Purchasers Cell Phone. This Purchaser can then attend a Health Service Provider in Prior&#39;s special designated Network, to redeem the Voucher &amp; obtain Treatment etc to value of the Voucher. There are many other adaptable Products, all listed in the enclosed Prior Investment Schedule.
The invention relates to a traditional Chinese medicine composition for treating lumbar disc herniation sciatica and application thereof, wherein the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 2 parts of aconite tip, 2 parts of arisaema tuber, 1 part of realgar, 1.5 parts of camphor, 1.5 parts of clove, 1.5 parts of dried ginger and 1.5 parts of evodia. The invention also comprises the application of the traditional Chinese medicine composition in preparing a medicine for treating lumbar disc herniation sciatica. Its advantages are: 1. the selected raw material medicines accord with the compatibility principle of &#39;monarch, minister, assistant and guide&#39; and have the advantages of good curative effect on treating the lumbar disc herniation sciatica and good curative effect on improving leg and waist pain. 2. The invention obtains the optimal proportion among the raw material medicines through experimental screening, and has good treatment effect. 3. The raw material medicine has no toxic or side effect, and the preparation method is simple and convenient, so that a new treatment scheme is provided for patients with lumbar disc herniation sciatica, and the practicability is strong.
NEW MATERIAL:A compound expressed by formula I [R is H or formula II (R&lt;1&gt; is alkyl, hydroxyalkyl, alkanoyloxyalkyl, alkoxyalkyl, aryloxyalkyl, heteroaryloxyalkyl, aryl or heteroaryl] or acid addition salt thereof. EXAMPLE:2-Amino-4-(5-acetylaminomethyl-2-furyl)thiazole.hydrochloride. USE:A medicine useful as a remedy for diseases, e.g. peptic ulcer, acute or chronic gastritis, acute gastric mucosal lesion, etc. having both acid inhibitory action and mucosal protecting action and further useful as an ameliorant of cerebral function having antihypoxic action. PREPARATION:A compound expressed by formula III (X is halogen) is reacted with thiourea to afford the compound expressed by formula I (R is acetoxy), which is then subjected to hydrolysis reaction to give the compound expressed by formula I (R is H). The resultant compound expressed by formula I is then reacted with a compound expressed by formula IV to provide the compound expressed by formula I (R is formula II and R&lt;1&gt;).
Methods for diagnosing chronic diarrhea and other gastrointestinal conditions. In the methods, a sample of gastrointestinal secretions is obtained from a control group; or a group who has been diagnosed with either healthy gastrointestinal tracts or with a gastrointestinal condition, like chronic diarrhea. The control group samples are analyzed in any suitable manner to determine the levels of gastrointestinal secretions, including one or more autophagy-related proteins, cytokeratins, digestive enzymes, or other proteins. The results of the sample analysis are used to create a database containing profiles of normal and abnormal gastrointestinal secretions. As the database is created and specific secretion level abnormalities are identified, patients may be diagnosed with these abnormalities and be treated by adjusting the levels of specific secretions. Gastrointestinal samples from subsequent patients may be analyzed and compared with the database to determine which of the patients&#39; secretion levels, if any, are abnormal.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a structured drug system that is useful for delivering a drug payload to a specific tissue or cell type.  &lt;P&gt;SOLUTION: The system is based on purified polymalic acid. This polymer isolated from natural sources is biocompatible, biodegradable and of very low toxicity. The polymer is extremely water soluble and contains a large number of free carboxyl groups which can be used to attach a number of different active molecules. In the examples disclosed N-hydroxysuccinimide esters of the carboxyl groups are used to attach such molecules. The active molecules include monoclonal antibodies to promote specific cellular uptake and specific pro-drugs such as antisense nucleic acids designed to modify the cellular metabolism of a target cell. The pro-drugs are advantageously linked by a somewhat labile bond so that they will be released under specific conditions.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
A pH sensitive chewing gum kit is provided. The kit may contain chewing gum incorporating a pH sensitive substance. When chewed, the gum may change it&#39;s color in response to the oral fluids or salivary pH level. The chewing gum kit may also contain chewing gum with or without artificial sweeteners and one or more pH sensitive members including at least one pH sensitive substance incorporated in at least one portion thereof. When a pH sensitive member is put in contact with oral fluids or saliva, before, during or after chewing the gum, the color of the pH sensitive substance may change to a color which depends on the oral fluids pH value. This color may indicate whether the gum still needs to be chewed in order to achieve a desired oral fluids pH level. The kit may also include a reference color scale for assisting the interpretation of the color changes of the gum or of the pH sensitive members by the user to inform the user whether the gum still needs to be chewed and, optionally, for informing the user of the approximate remaining chewing time required to bring the oral fluids pH level to a desired value. Preferably, the desired value is higher (more basic) than a critical pH level of 5.3.
PROBLEM TO BE SOLVED: To improve efficiency of a medical examination, by equipping a means to input inquiry information, a means to extract inquiry information dealt on a chart from the inputted inquiry information, a subjective data I/O part to be inputted by patient&#39;s subjective data, and a means to display the inquiry information on the subjective data I/O part onto an electronic chart system. SOLUTION: This inquiry system 12 is set in a waiting room and patient&#39;s answers to the inquiry are inputted. The inquiry information is transmitted to a consultation room through a network, etc. When a doctor designated a patient already inquired on the electronic chart, the system displays the electronic chart on the screen and an inquiry information extracting part 130 extracts the inquiry information dealt on the chart. Parts corresponding to subjective data such as the chief complaint, etc., are set on an S I/O part 1320 and parts corresponding to the basic information on a basic information I/O part 131. The doctor examines the patient referring the main complaint information and basic information and inputs the obtained patient&#39;s objective data, the doctor&#39;s judgement, and an examination plan into a problem I/O part 133, O I/O part 1321, etc.
This invention provides an isolated DNA molecule which is at least 30 nucleotides in length and which uniquely defines a herpesvirus associated with Kaposi&#39;s sarcoma. This invention provides an isolated herpesvirus associated with Kaposi&#39;s sarcoma. This invention provides an isolated peptide encoded by the isolated DNA molecule. Further, this invention provides an isolated DNA virus wherein the viral DNA is about 270 kb in size; wherein the DNA encodes a thymidine kinase; and wherein the viral DNA is capable of selectively hybridizing to a nucleic acid probe selected from the group consisting of SEQ. ID NOs:10-12. This invention provides an antibody specific to the peptide. Antisense and triplex oligonucleotide molecules are also provided. This invention provides a transgenic nonhuman mammal and a cell line containing at least a portion of the isolated DNA molecule. This invention provides a method of vaccinating a subject for KS, prophylaxis diagnosing or treating a subject with KS and detecting expression of a DNA virus associated with Kaposi&#39;s sarcoma in a cell.
The present invention relates to medicine for treating bone injury, particularly to medicine which is suitable for fracture, soft tissue injury, etc. and can be externally applied and orally administrated. The medicine for treating bone injury has the weight proportion of 45 to 60g of angelica, 40 to 60g of frankincense, 40 to 60g of myrrh, 40 to 70g of carbonizedsichuan dipsacus root, 20 to 50g of dragon&#39;s blood, 25 to 100g of safflower, 20 to 50g of notoginseng, 5 to 30g of pyrite, 5 to 10g of cinnabar, 50 to 80g of rhizoma drynariae, 30 to 60g of ground beetle, 10 to 30g of eucommia bark, 20 to 50g of muskmelon seed, 10 to 50g of cat head bone and 10 to 20g of pig jawbone according to each component, and 10 to 20g of cassia twig or 10 to 20g of twotooth achyranthes root can be added according to different kinds of nidus. Because several kinds of traditional Chinese medicine, such as rhizoma drynariae, cat head bone, pig jawbone, etc. are added, therapeutic effect after components are compounded is more obvious, and most of symptoms of fracture, bone injury, soft tissue injury, etc. are treated with the therapeutic method that internal injury and trauma are treated together, tendon and bone are regarded, and medicine is matched. The present invention has the advantages of quick pain alleviation, short course of treatment, low cost and has the effect of stasis absorption, bone promotion, tendon promotion and channel activation. Perennial practice proves that the present invention has favorable clinic effect and is worth popularizing.
PURPOSE:To obtain the titled compound useful as an antithrobotic drug, by condensing a benzothiazepine derivative with a dialkylaminoethyl halogenide. CONSTITUTION:A benzothiazepine derivative shown by the formula I (R&lt;1&gt; is lower lakyl) is condensed with a compound shown by the formula II (R&lt;2&gt; and R&lt;3&gt; are lower alkyl; X is halogen), and, if necessary, the condensation product is converted into an acid addition salt, to give the desired compound shown by the formula III or its acid addition salt. The reaction is carried out in a proper solvent in the presence of a base (e.g. NaOH) at 0-100 deg.C, preferably at 20-70 deg.C. The compound shown by the formula II can be obtained by hydrolyzing a novel benzothiazepine derivative shown by the formula IV (R&lt;4&gt; is lower aklanoyl). The compound shown by the formula IV can be obtained by reacting a compound shown by the formula V with a reactive derivative of a carboxylic acid shown by the formula R&lt;4&gt;OH in the presence of a compound shown by the formula (R&lt;5&gt;)2RO(R&lt;5&gt; is lower alkyl).
The serum is obtd. by injecting an animal, pref. a horse, over 6-8 weeks with lymphocytary prepns obtd. by mixing &gt;=5 pref. &gt;10 strains of permanent lymphoblastoid cultures from human subjects and 10-20 days after the final injection, recovering the serum from the blood. The serum is useful in transplant, treatment of autoimmune diseases, certain neurological disorders and certain inflammations. In an example, human leucocytes were cultured conventionally and after the establishment of permanent lines, nine such lines were mixed, injected subcutaneously into a horse in six weekly injections of 5 x 109 rising to 3 x 1010 cells. The serum was recovered 10 days after the last injection.
NEW MATERIAL:The tricyclic alcohol of formula I (one of R1 and R2 is H and the other is 1-8C hydrocarbon group, or both R1 and R2 are 1-8C hydrocarbon group or together form a 2-6C ring; R3 is H or 1-8C hydrocarbon group). EXAMPLE:9-Exo-ethyltricyclo[5,2,1,0&lt;2.6&gt;]decan-8-ol. USE:Useful as a chilling agent. It has physiologically refreshing effect, and is almost odorless. It is used to impart a refreshing and chilling effect to cosmetics such as beauty wash, perfumery, cream, lotion, etc., a deodorant, an anhidrotic, cleaning agents such as soap, champoo, etc., drugs such as ointment, external anti-inflammatory nd analgesic agent, etc. and foods such as chewing gum, etc. PREPARATION:The compound of formula I can be prepared by reacting the compound of formula III derivaed from cyclopentadiene of formula II with a halide, reacting the produced compound of formula IV with the compound of formula R2X (X is halogen), and finally reacting with an organometallic reagent.
PURPOSE:To obtain a soft capsule having transparent appearance and high commercial value, free from adverse effect on human body and producible at a low cost, by including a water-soluble substance in the skin membrane and an oily liquid in the content of the same capsule. CONSTITUTION:A water-soluble substance (e.g. pyridoxine hydrochloride or chlorpheniramine maleate) is dispersed in an oily liquid (e.g. wheat embryo oil or medium-chain fatty acid triglyceride). The dispersion is enclosed with a soft capsule skin composed mainly of gelatin, glycerol, etc., and the capsule is dried to obtain the objective soft capsule. The oily liquid may contain an oil-soluble substance such as tocopherol acetate, vitamin A, vitamin D or retinol palmitate as a solute. The amount of the water-soluble substance dispersed in the oily liquid is preferably &lt;=10wt.%, especially &lt;=5wt.%.
A medical monitoring device (5), operating system, and method is provided for managing administration of medical treatment regimens for treating a patient&#39;s medical conditions. The device stores information relating to the medical treatment regimens being administered, including medication schedule data, treatment data, patient query data, patient response data, and interactively provides the information to the patient and health care providers (105). A  method and apparatus for performing real-time monitoring of a patient&#39;s health status using a medical monitoring device (5) capable of wireless transmission, is also provided. Various aspects of the patient&#39;s treatment regimens are modified accordingly. The medical monitoring device (5) further analyzes monitored data in view of predefined criteria, and is capable of promptly communicating information concerning the patient&#39;s health status and treatment progress to remote devices (105) which notify appropriate health care providers, and is capable of modifying the patient&#39;s treatment regimens based on the results of the analysis. A system of monitoring devices and sensors are further provided for performing real-time monitoring and analysis of the patient&#39;s treatment regimens. The wireless monitoring facilitates various real-time tasks including, conducting a health status assessment, monitoring adverse effects experienced by the patient, monitoring treatment progress, assessing physiologic, cellular, molecular, endrocrine, and metabolic data, and assessing the patient&#39;s general quality of life.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide particles containing a lipophilic compound and having a narrow particle size distribution by covering the surfaces of droplets of the lipophilic compound unstable to water, light, oxygen, or the like.  &lt;P&gt;SOLUTION: A spiral gas flow is generated in a spray tower 1 by introducing a gas containing starch dispersed therein from a spout 3 installed in a side surface in the spray tower 1. An emulsified dispersion obtained by dispersing fat-soluble vitamins is sprayed from a nozzle 2 in the gas flow to form coated particles of the fat-soluble vitamins having the surface coated with the coating agent (starch). By the generation of the spiral gas flow, nearly uniform coated particles are formed because the retention time of the emulsified dispersion and the coating agent in the spray tower 1 is prolonged. As a result, the unstable fat-soluble vitamins are provided as coated particles having the narrow particle size distribution.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI